Clinical Trial Update: Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial [Phase 1, Phase 2]

View source ↗

Summary

Pilot trial investigating ex-vivo delivery of rituximab to prevent PTLD in EBV mismatch lung transplant recipients; Phase 1/2 study with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infections
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Epstein-Barr Virus Infections, Post-transplant Lymphoproliferative Disorder | Phase 1, Phase 2 | Status: UNKNOWN